Additionally, in one study, BRAF V600 mutant melanoma patients treated with vemurafenib, another BRAFi, were assessed of ctDNA plasma concentration using a ddPCR targeting the BRAF V600E/K mutation [80]. Here, BRAF is linked to melanoma.